Long non-coding RNAs associated with non-small cell lung cancer

Yuting Zhan, Hongjing Zang, Juan Feng, Junmi Lu, Lingjiao Chen and Songqing Fan _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:69174-69184. https://doi.org/10.18632/oncotarget.20088

Metrics: PDF 1353 views  |   HTML 2525 views  |   ?  


Yuting Zhan1, Hongjing Zang1, Juan Feng1, Junmi Lu1, Lingjiao Chen1 and Songqing Fan1

1Department of Pathology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China

Correspondence to:

Songqing Fan, email: [email protected]

Keywords: NSCLC, lncRNAs, chemotherapy, radiotherapy, molecular therapy

Received: May 01, 2017     Accepted: July 26, 2017     Published: August 09, 2017


Lung cancer, with 80–85% being non-small cell lung cancer (NSCLC), is the leading cause of cancer-related death in both men and women. Long non-coding RNAs (lncRNAs), always defined as non-protein-coding RNA molecules longer than 200 nucleotides, are now thought as a new frontier in the study of human malignant diseases including NSCLC. As researches continue, increasing number of roles that lncRNAs play in NSCLC has been found, and more and more evidences show lncRNAs have a close relationship with patients’ response to radiochemotherapy or molecular therapy. The aim of this review is to disclose the roles that lncRNAs play in NSCLC and how lncRANs influence the treatment of NSCLC.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 20088